Regenxbio Inc
Change company Symbol lookup
Select an option...
RGNX Regenxbio Inc
OGSYS Otis Gallery LLC
RDN Radian Group Inc
SLNO Soleno Therapeutics Inc
REI Ring Energy Inc
FSHOX Fidelity® Select Construction & Housing Portfolio
NNN NNN REIT Inc
UTHR United Therapeutics Corp
KEX Kirby Corp
DDOG Datadog Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.

Closing Price
$18.56
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Average)
Volume:
434,410

10-day average volume:
466,934
434,410

MetLife Inc. Stock Falls Thursday, Underperforms Market

5:09 pm ET February 23, 2023 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of MetLife Inc. (MET) sank 0.40% to $70.58 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 0.53% to 4,012.32 and the Dow Jones Industrial Average rising 0.33% to 33,153.91. This was the stock's third consecutive day of losses. MetLife Inc. closed $6.78 short of its 52-week high ($77.36), which the company achieved on November 25th.

Trading volume (3.6 M) remained 162,577 below its 50-day average volume of 3.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 23, 2023.

	

(END) Dow Jones Newswires

February 23, 2023 17:09 ET (22:09 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.